by University Health Network Credit: University Health Network A single-dose of the antiviral drug peginterferon lambda reduced by half the risk of hospitalization or a visit to the Emergency Department due to COVID-19, according to a study published today in the New England Journal of Medicine. The multi-center phase 3 TOGETHER clinical trial—designed to test a...
